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Background: Behavioral symptoms accompanying dementia are associated with increased health care costs,
reduced quality of life and daily functioning, heightened family caregiver burden, and nursing home placement.
Standard care typically involves pharmacologic agents, but these are, at best, modestly effective, carry serious risks,
including mortality, and do not address behavioral symptoms families consider most distressful and which may
prompt nursing home placement. Given dementia’s devastating effects and the absence of an imminent cure, the
Veterans Administration has supported the development and testing of new approaches to manage challenging
behaviors at home.
Methods/Design: The Tailored Activity Program – Veterans Administration is a Phase III efficacy trial designed to
reduce behavioral symptoms in Veterans with dementia living with their caregivers in the community. The study
uses a randomized two-group parallel design with 160 diverse Veterans and caregivers. The experimental group
receives a transformative patient-centric intervention designed to reduce the burden of behavioral symptoms in
Veterans with dementia. An occupational therapist conducts an assessment to identify a Veteran’s preserved
capabilities, deficit areas, previous roles, habits, and interests to develop activities tailored to the Veteran. Family
caregivers are then trained to incorporate activities into daily care. The attention-control group receives bi-monthly
telephone contact where education on topics relevant to dementia is provided to caregivers. Key outcomes include
reduced frequency and severity of behavioral symptoms using the 12-item Neuropsychiatric Inventory (primary
endpoint), reduced caregiver burden, enhanced skill acquisition, efficacy using activities, and time spent providing
care at 4 months; and long-term effects (8 months) on the Veteran’s quality of life and frequency and severity of
behavioral symptoms, and caregiver use of activities. The programs’ impact of Veterans Administration cost is also
examined. Study precision will be increased through face-to-face research team trainings with procedural manuals
and review of audio-taped interviews and intervention sessions.
Discussion: The Tailored Activity Program – Veterans Administration is designed to improve the quality of life of
Veterans with dementia and lessen the burden of care on caregivers. Activities are tailored to reflect the Veteran’s
preserved capabilities and interests to enhance active engagement, while not taxing areas of cognition that are
most impaired.
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Over 5 million Americans have Alzheimer’s disease or
related dementias, a progressive and irreversible neuro-
degenerative syndrome, with prevalence rates expected
to approach 14 million individuals by 2050 in the US [1].
As populations age worldwide, dementia diagnoses
are expected to increase dramatically and eventually
reach epidemic proportions. Among Veterans 65 and
older, rates of dementia are similar to the population
at-large, with 7.3% prevalence across all races, except
African-Americans, for whom the rate is 50% higher [2].
The prevalence rate of dementia across Veterans Inte-
grated Service Networks (VISNs) ranges from 5.8 to
9.4%, and the disease is associated with substantially
higher inpatient and outpatient service utilization rela-
tive to other VA patients [2].
Neuropsychiatric symptoms, also referred to as behav-
ioral and psychological symptoms, are a hallmark of de-
mentia, and include agitation, apathy, depression, mood
lability, aggressiveness and other behaviors families find
challenging, such as wandering, hoarding, disengage-
ment, or rejection or refusal of care [3]. Behavioral
symptoms are associated with increased health care
costs, reduced quality of life and daily functioning,
heightened family caregiver burden, and nursing home
placement [4,5]. Standard care typically involves
pharmacologic agents, but these are not FDA approved
for behavioral management in persons with dementia,
are, at best, only modestly effective, carry serious risks
including mortality, and do not address the behavioral
symptoms that families themselves consider most dis-
tressful or prompt nursing home placement [6,7]. Given
the disease’s devastating effects and the absence of an
imminent cure, medical organizations nationally and
internationally, including the VA, support the develop-
ment and rigorous testing of new approaches to manage
behavioral symptoms for persons with dementia living at
home.
A promising approach for addressing the behavioral
challenges associated with dementia is the use of ac-
tivity to engage the individual [8]. Preliminary evi-
dence suggests that activities tailored to the interests
and capabilities of persons with dementia can reduce
behavioral symptoms and improve quality of life
[9-11]. However, there is limited research on the ef-
fects of using activity at home to reduce behavioral
symptoms. Limitations of previous research include a
nearly exclusive focus on residents of nursing homes,
small sample sizes, and lack of randomized trial de-
signs. As most persons with dementia live at home,
testing this approach using randomized trial method-
ology with diverse populations has the potential for
practical real-world clinical application. This report
describes a protocol being used in an ongoingrandomized trial testing an activity intervention for
Veterans living at home with dementia.
Methods/Design
The TAP-VA study protocol received approval from the
Institutional Review Board at the University of Florida
and the Research and Development Committee of the
North Florida/South Georgia Veterans Health System in
Gainesville, Florida (IRB # 454–2011). TAP-VA program
staff engaged in readings including a detailed interven-
tion manual and participated in face-to-face 4-day onsite
training sessions. All project staff met University and VA
standards for research compliance and human subject
data collection. A data safety monitoring board was
formed, which reviewed and approved all study proto-
cols. General procedures involve a telephone screening
of family caregivers to determine eligibility, a home
interview to perform baseline data collection, stratified
randomization (by caregiver relationship (spouse versus
non-spouse) to Veteran), and intervention delivery
(Figure 1). All dyads are then retested at 4-months from
baseline, main study endpoint, and 8-months from base-
line at home to evaluate long-term effects (secondary
outcomes).
Aims and study hypotheses
Our primary study aim concerns the Veteran with de-
mentia and tests the immediate effect of TAP-VA at
4 months on behavioral symptoms. Our hypothesis is
that Veterans with dementia who receive TAP-VA will
manifest lower total scores on the Neuropsychiatric
Inventory (NPI), which assesses frequency and severity
of 12 common behavioral symptoms, compared to
Veterans assigned to an attention control group.
The study has four secondary aims; one relates to
Veteran participants, two relate to caregivers, and one
relates to the impact of TAP-VA on health related costs:
1) Test the long-term effects of TAP-VA at 8 months on
quality of life and behavioral symptoms of Veterans with
dementia. Hypothesis: Veterans receiving TAP-VA will
manifest higher quality of life and lower total NPI scores
over time (baseline to 8 months) in comparison to Vet-
erans in the attention control group; 2) Test the imme-
diate effects of TAP-VA at 4 months and long-term
effects at 8 months on caregiver burden, skill acquisition,
efficacy using activities, and time spent providing care.
Hypothesis: Caregivers receiving TAP-VA will report re-
duced burden, enhanced skills and efficacy using activ-
ities, and less time providing care compared to the
control group at 4 and 8 months; 3) Examine whether
caregivers receiving TAP-VA are using activities at
8 months; and 4) Examine whether TAP-VA results in
reduced Veterans Health Administration (VHA) health
care use and costs for Veterans with dementia and their
Figure 1 Flowchart of study design.
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vide further evidence of treatment efficacy, identify
whether booster sessions are necessary, and inform
dissemination efforts and translation of TAP-VA system-
wide.
Setting
If this approach is proven efficacious, our long-term ob-
jective is to integrate TAP-VA into standard care prac-
tices within the VHA system as the first treatment
choice for addressing behavioral symptoms in Veterans
with dementia living at home. This would transform the
current paradigm of dementia care which relies on
pharmacologic management.
The VHA is the largest integrated healthcare system in
the nation and provides taxpayer-financed healthcare to
honorably discharged Veterans of the United States
Armed Forces [12,13]. Parallels are sometimes drawn
between the VHA and other nationalized healthcare
services, although priority within the VHA is generally
granted to Veterans with service-related disabilities, low
incomes, and extended terms of service. The VHA main-
tains a multi-billion dollar electronic health record sys-
tem that supports communication across its twenty-one
Veteran Integrated Service Networks (VISNs) and nearly
300,000 employees [14]. Service connectivity across the
VHA allows for numerous sources of referral to TAP-
VA to include home care services, rehabilitation services,
and physician referral. If TAP-VA is shown to be effect-
ive, referral to occupational therapists trained in TAP-VA for home delivery could be offered as a supplemental
service within the existing home care structure.
Study procedures, eligibility and randomization
Our recruitment and enrollment procedures primarily
target the caregiver of VA patients in geriatric VA ser-
vice programs. Recruitment primarily involves mailings
to families identified through the VA services. The mail-
ing includes a descriptive IRB approved flyer about the
study and a letter from the medical director of the ser-
vice explaining study procedures and inviting study par-
ticipation. Caregivers are directed to contact either the
research team by telephone or to return a postcard in a
self-addressed and stamped envelope indicating an inter-
est in learning more about the study.
Caregivers contacting the research team receive an ex-
planation of study procedures, and if interested in par-
ticipating in the study, complete a brief telephone screen
to determine eligibility. For caregivers eligible and will-
ing to participate, a baseline interview is conducted by a
trained interviewer within 2 weeks of determination of
eligibility, and prior to randomization to study group. At
the time of the interview, the Mini-Mental State Exam-
ination (MMSE) is administered to the Veteran. For Vet-
erans with MMSE scores greater than 23, a review of the
participant’s medical chart to confirm a current diagno-
sis of dementia is performed. Following the baseline
interview, dyads eligible and willing to participate are
randomized (see data analytic considerations) to the
TAP-VA treatment group or an attention control group.
Gitlin et al. BMC Geriatrics 2013, 13:96 Page 4 of 9
http://www.biomedcentral.com/1471-2318/13/96Inclusion criteria for Veterans with dementia include:
1) English speaking; 2) diagnosis of dementia; 3) able to
participate in at least two activities of daily living (ADLs
- bathing, dressing, grooming, toileting, transferring
from bed to chair); 4) not currently participating in any
other dementia-related intervention; and 5) score of 23
or less on the MMSE or if higher, confirmation of a phy-
sician’s diagnosis. Specifically, Veterans with diagnosis
codes 290.0, 290.2, 290.3, 331.2 (senile dementias), 290.4
(vascular dementia), 294.8 (dementia not otherwise
specified), 331.0 (Alzheimer’s disease), 331.1 (frontotem-
poral dementia), and 331.82 (Lewy body dementia) are
considered to have dementia diagnoses and are thus
eligible for study participation.
If the Veteran with dementia is on any of four classes
of psychotropic medications (antidepressant, benzodiaz-
epines, antipsychotic, or anti-convulsant) or an anti-
dementia medication (memantine or a cholinesterase
inhibitor), we require that he/she have been on a stable
dose for 60 days (the typical time frame used in clinical
trials) prior to enrollment to minimize possible confoun-
ding effects of concomitant medications.
Caregivers of Veterans must be: 1) English speaking; 2)
self-identify as the primary member of the family caring
(hands-on or supervision) for the Veteran; 3) 21 years of
age or older (male or female); 4) living with the Veteran;
5) accessible by telephone to schedule interviews, inter-
vention sessions, and follow-up interviews; 6) planning
to live in the area for 8 months (to reduce loss to
follow-up); 7) willing to learn how to use activities; 8) re-
port one or more behavioral symptoms in the Veteran in
the past month; and 9) not currently participating in any
other caregiver-related intervention. Finally, we require
that caregivers taking a psychotropic medication (e.g.,
antidepressant, benzodiazepines, antipsychotic, or anti-
convulsant) at time of telephone screen be on a stable
dose of the medication for 60 days prior to enrollment.
A rolling recruitment schedule will continue until 160
Veterans living at home with dementia and whose care-
givers report one or more behavioral symptoms are
enrolled.
Sample Size is based on: a) one primary outcome (NPI
at 4 months); b) treatment effect sizes for outcomes from
the TAP pilot study; and c) ability to detect a medium
effect size of 0.50. We will use a type I error rate of .05 for
the single primary hypothesis. We seek to detect a moder-
ate effect size (a 0.5 standard deviation difference). A
smaller effect size brings us at or near levels where the
study could have statistical but not clinical significance
[i.e., number needed to treat (NNT) of 4.5]. In order
for an intensive, targeted intervention to be worth
implementing, it must yield more than trivial effects.
Since our planned analyses are primarily analyses of
covariance with baseline as the covariate, we calculatethe power of a two-sample t-test on change scores from
baseline to 4 months. Because we will be using analyses
of covariance to adjust for baseline, we expect to have
greater precision and power than indicated here. To
attain 80% power for a two-sided alternative hypothesis
using a t-test comparing the two treatment groups with
respect to 4-month values will require 64 dyads per
group. However, we plan to recruit an additional 16 per
group or 32 dyads for a total of 160 (80 per group).
Thus, to obtain the necessary sample size of 128, 160
will need to be enrolled.
Veterans with dementia diagnostic codes (listed in in-
clusion criteria) are recruited from the North Florida/
South Georgia Veterans Health System Geriatric Re-
search, Education & Clinical Center and Geriatrics and
Extended Care Service outpatient services, including the
Home Based Patient Care and Homemaker Home
Health Aide program. Our recruitment efforts will also
include independent senior living facilities, adult day
services, and support groups.
All eligible dyads receive a baseline home interview
(Table 1) and then are randomized to either the
experimental (TAP-VA) or attention-control groups.
Randomization is stratified by the caregiver’s relation-
ship to the Veteran (spouse vs. non-spouse) to ensure
that the two intervention groups are balanced with re-
spect to this factor. Type of relationship has previously
been associated with treatment processes, outcomes,
and study attrition [15]. For randomization within each
stratum, the method of random permuted blocks is used
to control for possible changes over time in the subject
mix. The blocking number was developed by the project
statistician, and is not disclosed to the investigators or
other members of the project team. The project statisti-
cian provides the necessary materials and randomization
list to a research staff member who is not involved in
study oversight, intervention, or interview. This individ-
ual prepares consecutively numbered randomization en-
velopes which contains the group allocation information
on a piece of paper folded over multiple times to ob-
scure the information, and provides the envelopes to the
project coordinator. The project coordinator then ran-
domizes a subject by opening the next available envelope
for the appropriate stratum (spouse/non-spouse). The
randomization procedure occurs after the baseline as-
sessment. Families who do not wish to continue in the
study after the interview will not be randomized and not
count towards accrual goals.
Interviewers are masked to group allocation. Inter-
viewers and interventionists do not share office space
and staff meetings do not involve discussion of study
participant allocation. Additionally, caregivers are asked
not to discuss their group assignment with interviewers.
Following each follow-up interview, the interviewer is
Table 1 Assessment measures
Measure Purpose When assessed
Investigator-Developed Semi-Structured
Interview
Collects demographic information, CG health and behavior,
confidence in meaningful activity, vigilance, mastery and control,
leisure frequency and amount, CG and Veteran medication use.
Baseline (T1) Interview,
4-Month (T2) Interview,
8 Month (T3) Interview
Mini Mental State Exam (MMSE) Screening to detect cognitive impairment. Also used
to verify inclusion criteria.
Baseline (T1) Interview
Caregivers Assessment of Functional
Dependence and Upset (CAFU)




8 Month (T3) Interview
Neuropsychiatric Behavior Inventory (NPI-C) Measures behavioral disturbances in Veteran with dementia. Baseline (T1) Interview,
4-Month (T2) Interview,
8 Month (T3) Interview
Quality of Life AD (QOL-AD) Detects a rating of the Veteran's quality of life. Baseline (T1) Interview,
4-Month (T2) Interview,
8 Month (T3) Interview
The Center for Epidemiologic Studies
Depression Scale (CES-D)
Measures the depressive symptomology of the caregiver. Baseline (T1) Interview,
4-Month (T2) Interview,
8 Month (T3) Interview
Zarit Short Form Burden Scale Measures caregiver burden in relation to time, developmental




8 Month (T3) Interview
Task Management Strategies Index (TMSI) Identifies actions taken by caregivers to simplify everyday
self-care tasks for individuals with dementia.
Baseline (T1) Interview,
4-Month (T2) Interview,
8 Month (T3) Interview
Dementia Management Strategies
Scale (DMSS) Short Version
Identifies the frequencies with which caregivers use a variety




8 Month (T3) Interview
Allen Diagnostic Module ( 2nd Edition) Provides opportunities to observe global cognitive processing
capacities, learning potential, and performance abilities to detect
unrecognized or suspected problems of functional cognition.
OT Intervention, Period 1
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was assigned, and the reason for their guess. This pro-
vides a way to monitor assignment disclosures and track
any off protocol occurrences with regard to unmasking.
Recruitment progress
Recruitment procedures have been implemented and
will continue for a total of 33 months, with approxi-
mately 5 dyads enrolled per month. To date, we have
enrolled 41 participants from 362 initial mailings sent
starting April, 2012, and again to non-respondents in
August, 2012. Of the first two mailings, 64 (17.6%) re-
sponses were received via telephone or postcard, of
which 41 (64%) were eligible, willing to participate, and
enrolled. This recruitment rate mirrors our initial goal
of 5 dyads per month. An additional 185 mailings have
been sent in June and July of 2013 to newly identified
Veterans. Eleven letters have also been sent to localrehabilitation clinics, VA clinics, and adult care facilities
for study outreach and to aid recruitment.
Reasons for ineligibility have included dependent feed-
ing (bringing food to mouth), disinterest after telephone
screen, imminent nursing home or hospice placement,
move outside of study radius, and death of Veteran with
dementia. Attrition between baseline and randomization
is currently 2 (4.8%). Attrition after randomization is
currently 11(26.8%) due to: Veteran death [4], Veteran
illness [4], and caregiver-initiated withdrawal [3]. This is
slightly above our expected overall attrition rate of 20%.
TAP-VA intervention
The intervention is designed to draw on spared or re-
sidual abilities of Veterans with dementia and provide an
environment supportive of these abilities. Occupational
therapists (OTs) conduct an assessment of the person’s
home environment, preserved capabilities, daily routines
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use activities. This assessment uses a combination of
caregiver and Veteran self-report, direct observations
and performance-based tests. Based on the assessment,
activities are developed that reflect the Veteran’s previ-
ous or current interests and are then modified to match
the person’s preserved capabilities without taxing the
most impaired areas of cognition (e.g., memory, new
learning). In designing activities, the occupational ther-
apist interventionists simplify an activity and structure it
to focus on single rather than multiple or complex tasks,
thereby minimizing potential for the Veteran to make
errors.
The activity environment is constructed to provide
auditory or tactile cues to facilitate recall and guide initi-
ation and sequencing. By grading activities to match the
Veteran’s capabilities, the occupational therapist inter-
ventionists minimize demands that may heighten stress
(e.g., high functioning individuals will be introduced to
more goal-directed and multi-step activities, whereas
lower functioning individuals will be introduced to activ-
ities that are based on repetitive motion (e.g., washing
windows, folding towels) and integrate multi-sensory
stimulation (e.g., soft music, objects pleasant to touch).
Whereas other activity interventions may emphasize
new learning, our approach does not, although it may
entail some procedural learning if appropriate.
TAP-VA provides caregivers with the requisite know-
ledge and skills to use activities. Caregivers are
instructed in specific skills such as ways to simplify ac-
tivities, the environment and their communication, and
how to help the Veteran initiate and follow a sequence.
The overall goal is to provide predictability, familiarity,
and structure in the daily life of the Veteran and estab-
lish a level of environmental stimulation appropriate to
that person’s abilities. Three clinical elements are used
to enhance caregiver receipt and enactment of interven-
tion strategies: 1) the interventionist engages caregivers
(versus being prescriptive) in learning how to use activ-
ities by modeling, simulating, role play and direct dem-
onstration with the Veteran, 2) the caregiver is provided
repeated opportunities for practice and modification of
techniques, and 3) the interventionist uses validation
and actively demonstrates techniques within the context
of their use.
To enhance effective use of activity, caregivers are pro-
vided concrete knowledge as to what the Veteran is cap-
able of doing (e.g., can grasp object such as a plate) and
his/her specific limitations (e.g., needs verbal cueing to
place dish in cabinet). With this knowledge, interven-
tionists can help caregivers restructure their expecta-
tions, behavioral goals, and reactions to the Veteran.
During treatment sessions, caregivers are taught to: 1)
recognize capabilities and deficits, 2) translate capabi-lities into objective activity goals, and 3) generate spe-
cific steps to set up activities and help caregivers initi-
ate/sequence.
Attention control group
The attention control group serves three purposes: 1)
creates clinical equipoise, ensuring that ethical treatment
is provided to all study participants; 2) controls for the
one-on-one attention to caregivers in the Tailored Activ-
ity treatment group to rule out potential effects of pro-
fessional contact; and 3) serves as a retention tool to
keep control group caregivers meaningfully connected to
the trial. Caregivers in this group receive bi-weekly tele-
phone contact (up to 8 contacts) by a trained healthcare
professional. In each session, caregivers are provided im-
portant information about dementia and strategies for
managing the disease at home (Table 2). Each telephone
contact is approximately 30 minutes in length and be-
gins with a brief overview of the specific purpose of the
session, followed by a description of the key facts about
the session topic, and concludes with a question and an-
swer period. Table 2 outlines the specific domain and
session content that is covered. The attention control
group intervention is delivered by a member of the re-
search team who is knowledgeable about dementia and
has had prior experience working with family caregivers.
Analytic plan
Descriptive analyses and univariate comparisons of the ex-
perimental and control group conditions using Chi-square
and Wilcoxon rank-sum tests will be performed as appro-
priate. If any imbalance (large or statistically significant
difference) is found on important prognostic factors, those
factors will be forced into all ANCOVA’s. Chi-square and
Wilcoxon rank-sum tests are performed as appropriate to
identify differences between experimental and control
group at baseline. In addition to serving as a final data
quality check, these analyses are used to characterize the
study population, assess the success of randomization in
balancing the two groups, and determine the impact of
any dropouts on that balance with respect to potentially
important prognostic factors (e.g., age, education level of
Veteran, MMSE score).
Experiences in earlier trial phases suggest that attrition
is an external, rather than an internal validity problem.
That is, while those who drop out differ from those who
remain, the control and intervention groups remain
comparable. This is an important consideration for ana-
lysis, so the internal validity comparison is part of these
initial analyses. Experimental and control group subjects
who remain at T2 are compared on their baseline char-
acteristics to determine whether the groups remain com-
parable (internal validity). This comparison also occurs
for dyads remaining at T3. If any imbalance (large or
Table 2 Attention-control group
Domain Brief description of content
Education About dementia Overview of key facts about dementia as a degenerative disease that currently has no cure.
General Safety Issues Information about safety issues inside and outside the home, the types of safety hazards
to be aware of, and how to make the environment safer for the Veteran and caregiver.
Home Safety Room-by-Room Information about preventing accidents by doing a room safety check in the home and
tips for making each room safer for the Veteran and caregiver.
Being a Medical Advocate for your Veteran Suggestions for the caregiver about working with healthcare providers and other members
of the health care team to ensure the Veteran receives the best care possible.
Taking Care of Yourself as a Caregiver Tips for the caregiver about taking care of their own social, physical, recreational, and other
needs so that they may continue to provide quality care for their Veteran.
Behavior Problems Education about behavior problem areas and suggestions for preventing or mediating
unwanted or harmful behaviors associated with dementia.
Activities for the Veteran and Caregiver Suggestions for engaging the Veteran and caregiver in activities and information about
that benefits from participation in activities designed specifically for them.
Summary Brief summary of the previous 7 session topics and an opportunity for caregiver feedback
about educational sessions.
Gitlin et al. BMC Geriatrics 2013, 13:96 Page 7 of 9
http://www.biomedcentral.com/1471-2318/13/96statistically significant difference) is found on important
prognostic factors, highlighted factors will be forced into
all ANCOVA’s.
Covariates such as comorbidities, disease stage, psy-
chotropic medication use, caregiver relationship, and
gender are also considered. Although it may be of inter-
est to evaluate treatment effect on long-term/permanent
nursing home placement, significant sample size and re-
cruitment might not be possible. All analyses utilize
current versions of SPSS, SAS, and Statistica.
The primary endpoint is the NPI index (total summary
score reflecting frequency by severity) at 4-months. The
focus of the primary analysis is to examine the effect of
the intervention based on "intention to treat." Data from
all dyads, randomized to the experimental group, will be
part of the primary analyses regardless of actual number
of completed intervention sessions. This approach tests
the effect of the intervention without taking into ac-
count the extent to which dyads actually receive inter-
vention and effectively penalizes the intervention if
dyads are not willing to receive it or if dyads receive dif-
ferent doses or exposure to treatment. The adjusted
mean differences in treatment effects on the outcome
measure at 4 months are calculated using analysis of
covariance. Covariates include the baseline value of the
outcome measure, the stratification variable (spouse vs.
non-spouse) and other background characteristics if
large or statistically significant differences between
experimental and control group dyads are recognized.
For the ANCOVA analyses, a test of the normality
assumption for the dependent measure is performed by
examining distribution of residuals. If the residual distri-
bution is skewed, a transformation of the data will be
used. A similar approach will be used for secondary
aims. Examination of whether TAP-VA has a long-term
treatment effect at 8 months (T1-T3) on total NPI indexis performed by using ANCOVA analysis controlling for
baseline, stratifying and other potential covariates (e.g.,
comorbidities). The other secondary endpoints address
caregiver burden (Short Zarit Burden scale, upset with
behaviors, and time spent in care (2 vigilance items), and
skill acquisition (Task Management index)). The same
analytic procedure as described for Aim 1 is followed for
T2 and T3 data analysis.
Cost-effectiveness analysis
A cost-effectiveness analysis of the TAP-VA intervention
treatment group compared to the attention control
group will be performed using an innovative approach
for constructing incremental cost-effectiveness ratios
[16]. Rather than using Quality-Adjusted Life Years
(QALYs) as the measure of effectiveness, cost-effective-
ness is measured as the cost of achieving one additional
unit of benefit as defined by caregiver hours per day
“doing things” and hours per day “being on duty.” These
measures have advantages over QALYs in this applica-
tion, including: 1) their focus on a proximate caregiver
outcome of the TAP-VA intervention and 2) the ability
to compare this cost per unit time measure to both care-
giver opportunity costs and willingness-to-pay estimates
from previous studies [17], thereby avoiding issues re-
lated to the possible lack of sensitivity of QALY mea-
sures to the intervention and debates over appropriate
QALY valuation thresholds. These two time measures
are derived from the 4-item Caregiver Vigilance Scale
used in the Resources for Enhancing Alzheimer’s Care-
givers Health (REACH I) study [18].
Total costs of care for both groups will be compared
using a combination of existing VA patient-specific cost
data, direct cost measurement, and patient/caregiver
cost diaries. VA patient-specific costs originate from
the VHA’s Decision Support System (DSS) National Data
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counting system where specific costs are assigned to
specific cost centers, and costs from indirect cost centers
(commonly thought of as “overhead”) are allocated to
direct cost centers (those which produce patient care)
using standard step down allocation methods. For those
elements of the TAP-VA intervention not adequately
captured in the DSS NDEs, direct cost measurement will
be used [20,21]. In addition, cost diaries [22] will be used
to capture the indirect costs associated with care-related
travel, work-loss days, and out-of-pocket expenses in-
curred by the Veteran and caregiver.
Validation of the DSS NDE cost data will be performed
by merging DSS with the VA's Health Economics
Resource Center (HERC) Average Cost Dataset, which
provides encounter-level regression- and relative value
unit-based VA cost estimates using Medicare cost struc-
tures applied to VA patient and facility characteristics.
This is in accordance with HERC guidance, which rec-
ommends using the HERC Average Cost data as a valid-
ation check for the DSS cost data. In addition, costs for
patients who are eligible for and receive Medicare ser-
vices will be obtained using actual Medicare payments
from CMS Medicare data provided through the VA
Information Resource Center (VIReC). While Medicare
payments include a nominal profit margin, such margins
are specifically sized to approximate a normal return on
providers’ invested capital, and hence can be taken as
approximate measures of the total (variable plus fixed)
costs of care. Nevertheless, because Medicare payments
are qualitatively different from VHA DSS costs, these
Medicare dollars will be tallied separately from and
compared to VHA costs of care. If statistically significant
differences are found, the sensitivity of cost results to
the use of Medicare payments vs. VHA costs are ex-
plored further.
As it is difficult to distinguish costs specifically
influenced by the intervention using observational data,
cost is assessed over a 12 month period by summing all
inpatient and outpatient costs for each patient in the
sample. By so doing, external or “spillover” cost effects
of the intervention will be captured, thereby providing a
more accurate and comprehensive measure of the im-
pact of the intervention. Cost models will follow cus-
tomary practice and use the natural logarithm of
patient-specific costs as the dependent variable to ac-
count for the inherent skewness of cost data. Duan’s
smearing retransformation estimator corrected for hete-
roskedasticity will be used in calculating cost predictions
from the models. Because the sample consists of
chronically-ill patients, it is not anticipated that any sub-
ject will have zero costs in the data. Consequently, there
is not an expected need to estimate a two- or four-part
model to account for any large probability mass at zerocosts. However, if a significant number of patients with
zero values in the time-specific cost variables exists, a
two- or four-part model will be employed as necessary.
The cost hypothesis will be tested using the F-test in the
cost regressions for the overall rehabilitation settings
construct, supplemented by the t-tests for each setting.
If the incremental cost-effectiveness ratio measures
prove sensitive to denominators close to zero in absolute
value, the treatment and control arms are compared
using the net monetary benefit approach in order to
avoid the discrepancy [23].Discussion
TAP-VA is testing the effectiveness of an individualized
Veteran-centric intervention to reduce behavioral symp-
toms and improve quality of life. Secondarily, we will de-
termine the potential reduction in time caregivers spend
in care, and increase in caregiver skills as they relate to
incorporating activities into daily routines. We also seek
to evaluate potential cost savings in terms of health care
utilization rates of both Veterans and family caregivers
using a cost diary. Current recruitment rates imply suffi-
cient design and planning and suggest moderate popula-
tion interest in the program. Attrition rates to date are
modest and as expected for the population due to their
complex medical diagnoses and care situations associ-
ated with dementia and aging. The employed design is
an advancement over previous activity studies in that it
focuses on persons at home, tests an approach that fam-
ilies can use themselves in daily care, adheres to ran-
domized trial methodology, and includes a prospective
cost analysis that will enhance its eventual translation
and implementation potential.
If TAP-VA is efficacious and cost-effective, it will rep-
resent a promising approach for addressing behavioral
symptoms associated with dementia and caregiver bur-
den, warranting replication and implementation within
the Veterans Administration, as well as other healthcare
systems. In conclusion, TAP-VA is underway with a
Veteran population, though the originating intervention
components and principles have high transferability to
other dementia populations and settings.
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